MJ33-OH (lithium)

MJ33-OH lithium is a metabolite of MJ33. MJ33 is an active-site-directed, specific, competitive, and reversible phospholipase A2 (PLA2) inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6[1].

Product Specifications

CAS Number

[1135306-36-3]

UNSPSC

12352211

Target

Phospholipase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/mj33-lithium.html

Purity

90.0

Solubility

10 mM in DMSO

Smiles

O=P(OCO)(O[Li])OC(COCCCCCCCCCCCCCCCC)COCC(F)(F)F

Molecular Formula

C22H43F3LiO7P

Molecular Weight

514.48

References & Citations

[1]Shanshan Y, et al. Phospholipase A2 of Peroxiredoxin 6 Plays a Critical Role in Cerebral Ischemia/Reperfusion Inflammatory Injury. Front Cell Neurosci. 2017 Apr 5;11:99.|[2]Moawad AR, et al. Deficiency of peroxiredoxin 6 or inhibition of its phospholipase A2 activity impair the in vitro sperm fertilizing competence in mice. Sci Rep. 2017 Oct 11;7 (1) :12994.|[3]Fisher AB, et al. Altered lung phospholipid metabolism in mice with targeted deletion of lysosomal-type phospholipase A2. J Lipid Res. 2005 Jun;46 (6) :1248-56.